Top Importers of Ambergris, Civet, Musk for Pharmaceutical Use

In 2023, Hong Kong led as the top importer of ambergris, civet, and musk for pharmaceutical use, valuing at $46.2 million USD. Brazil and New Zealand followed closely, with imports valued at $28.88 million USD and $28.68 million USD respectively. South Korea and Japan were also significant players, with South Korea at $26.0 million USD and Japan at $17.18 million USD. The United States and Germany, traditionally strong markets, showed lower import figures at $9.82 million USD and $17.06 million USD respectively. France, Argentina, and Canada, with their respective values below $9 million USD, were notable but less dominant in the market.

• Hong Kong: $46.2 million
• Brazil: $28.88 million
• New Zealand: $28.68 million
• South Korea: $26.0 million
• Japan: $17.18 million
• Germany: $17.06 million
• United States: $9.82 million
• France: $8.89 million
• Argentina: $7.66 million
• Canada: $5.97 million

Future trends suggest that the demand for natural and sustainable ingredients in pharmaceuticals may drive increased imports in emerging markets. Continued regulatory changes and consumer preferences may also influence shifts in import volumes and values, with a potential rise in newer markets and alternative sourcing.